- Home
- FENC vs EARN Comparison
FENC vs EARN Comparison
Compare FENC & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- EARN
- Stock Information
- Founded
- FENC 1996
- EARN 2012
- Country
- FENC United States
- EARN United States
- Employees
- FENC N/A
- EARN N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- EARN Real Estate Investment Trusts
- Sector
- FENC Health Care
- EARN Real Estate
- Exchange
- FENC Nasdaq
- EARN Nasdaq
- Market Cap
- FENC 156.9M
- EARN 187.6M
- IPO Year
- FENC 2001
- EARN 2013
- Fundamental
- Price
- FENC $5.95
- EARN $5.37
- Analyst Decision
- FENC Strong Buy
- EARN Buy
- Analyst Count
- FENC 2
- EARN 2
- Target Price
- FENC $14.00
- EARN $5.88
- AVG Volume (30 Days)
- FENC 50.4K
- EARN 452.8K
- Earning Date
- FENC 05-20-2025
- EARN 05-20-2025
- Dividend Yield
- FENC N/A
- EARN 17.89%
- EPS Growth
- FENC N/A
- EARN N/A
- EPS
- FENC N/A
- EARN 0.28
- Revenue
- FENC $47,538,000.00
- EARN $41,240,000.00
- Revenue This Year
- FENC $2.68
- EARN N/A
- Revenue Next Year
- FENC $71.63
- EARN $16.66
- P/E Ratio
- FENC N/A
- EARN $19.21
- Revenue Growth
- FENC 123.69
- EARN N/A
- 52 Week Low
- FENC $3.96
- EARN $4.33
- 52 Week High
- FENC $10.07
- EARN $7.26
- Technical
- Relative Strength Index (RSI)
- FENC 51.33
- EARN 48.29
- Support Level
- FENC $5.85
- EARN $5.33
- Resistance Level
- FENC $6.61
- EARN $5.48
- Average True Range (ATR)
- FENC 0.36
- EARN 0.13
- MACD
- FENC 0.06
- EARN 0.02
- Stochastic Oscillator
- FENC 54.20
- EARN 23.91
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.